In order to study the echocardiographic abnormalities in consecutive patients with malignant phase hypertension (MHT), we reviewed echocardiograms of 31 patients (23 male; mean age 52714 years) with MHT who were admitted to our unit. Trans-thoracic echocardiography was carried out in all patients, and echocardiographic measurements were compared with those of 39 patients (30 male; mean age 54710 years) with controlled nonmalignant essential hypertension, and 32 (19 male; mean age 51710 years) healthy normotensive volunteers. Patients with MHT had a significantly higher mean systolic and diastolic blood pressure (Po0.001) compared to the other two groups. MHT patients had significantly greater mean left atrial dimensions (P ¼ 0.002), as well as aortic root dimensions (P ¼ 0.01) and left ventricular (LV) dimensions (with the exception of the diastolic internal diameter) (Po0.001). MHT patients also had a mean larger LV mass and LV mass index (both Po0.001) when compared to the other two groups. The mean ejection fraction was also lower in the MHT group (Po0.001). In conclusion, patients with MHT have significant cardiac hypertrophy, in association with systolic dysfunction and dilated left atria, irrespective of the duration of known hypertension. These abnormalities may predispose MHT patients to cardiovascular complications including heart failure and cardiac arrhythmias, such as atrial fibrillation.
Introduction
Malignant hypertension (MHT) is defined clinically as the presence of very high blood pressures (BP) in association with bilateral retinal flame shaped haemorrhages, cotton wool spots and hard exudates, with or without papilloedema. 1 It is not the BP itself that determines whether or not a patient has MHT, as the BP in severe nonmalignant hypertension may be quite as high as that seen in MHT, but there are no retinal changes and the outlook is less severe. 2 The importance of identifying MHT lies in the fact that, if untreated, it carries a very poor prognosis with a 5-year survival rate of 1%. [2] [3] [4] With improved healthcare and the availability of effective antihypertensive agents, this survival rate has improved to around 60-75% in 5 years. 5, 6 However, in developing countries such as Nigeria, the 1-year survival rates are much lower, at around 40%. 7 As hypertension has such a profound effect on the cardiovascular system, we postulated that MHT would result in more abnormalities in echocardiographic parameters, compared to nonmalignant hypertension and normotensive controls. We have published an earlier small series on echocardiographic changes in MHT, 8 and are now extending this work to include more MHT patients who have been seen since then, including a comparison with patients with nonmalignant essential hypertension and normotensive healthy controls.
Patients and methods
The study population included all patients who were admitted to City Hospital with a diagnosis of MHT during the preceding 6 years. To qualify for the diagnosis of MHT, the patient had to have raised BP, in association with bilateral retinal changes of haemorrhages, cotton wool spots, exudates with or without papilloedema confirmed by retinal photography.
Patients with MHT were compared with 40 age-, sex-and ethnic-group-matched patients with nonmalignant hypertension (which included patients with newly diagnosed untreated hypertension, who were matched with the 'new' MHT patients who were not receiving treatment). This was to remove any bias that duration of hypertension may have on the echocardiographic findings. Of these 40 nonmalignant hypertensive patients, one patient did not have suitable echocardiographic images. We also recruited 35 age-, sex-and ethnic-group-matched normotensive controls. Of these patients, only 32 had echocardiograms that were of suitable quality (see below). All hypertensive patients had an electrocardiograph (ECG) and the Sokolow-Lyon criteria was used to determine whether patients had left ventricular hypertrophy (LVH) or not. The sum of the greatest R wave in either V5 or V6 and the deepest S wave in either V1 or V2 greater than 37 was taken to be indicative of ECG-LVH.
Echocardiography
Echocardiography was performed using standard transthoracic views with a Vingmed 5 machine (GE Medical Systems Ltd, Slough, UK). Images were stored onto an optical disc and also recorded on a VHS videotape. M-mode images with cuts through the aortic root and the left ventricular wall, in the parasternal long axis view were obtained for left ventricle (LV) and left atrial (LA) measurements, while apical four chamber views were used for Doppler measurements across the mitral valve.
With respect to image quality, we used the same criteria for grading the quality of the echocardiograms as other studies have done. 9 If the right and left septal and endocardial and epicardial LV posterior wall interfaces could be seen along the entire cycle from which measurements were made, studies were scored as 'excellent' (publication quality) or 'good' (slightly less optimal edge definition). A score of 'fair' implied that at least 5 mm of continuous interface could be seen for each of these four interfaces on contiguous beats but not necessarily on the same beat. A score of 'poor' implied that portions of each interface sufficient to make a measurement could be extrapolated form three consecutive cycles. The LV was scored as 'unmeasureable' if one or more of the four (septal or LV posterior wall) interfaces could not be identified. Of the 35 echocardiograms of patients with MHT that were reviewed, only 31 had echocardiograms that were excellent, good or fair. Those that were graded as poor or unmeasureable were not included in the study. Similarly, 39 of the 40 patients with nonmalignant hypertension, and 32 of the 35 normotensive controls had images that were in the excellent, good or fair quality.
M-mode measurements were made according to conventions established by the American Society of Echocardiography. 10 LV mass was derived from the formula described by Devereux et al.
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Thus, the LV mass (in g) was calculated as 0.8 Â 1.04
where IVSd is the interventricular septal thickness in diastole, LVIDd is the left ventricular internal diameter in diastole and LVPDd is the left ventricular posterior wall at end diastole. The relative wall thickness (RWT) was defined as the ratio of twice the LVPWd and the LVID. The LV mass index was calculated as the LV mass corrected for body surface area. For the diagnosis of LVH on echocardiographic criteria, we followed the criteria that have been published previously and widely used. [12] [13] [14] Indexed LV mass greater than 110 g/m 2 in women and 125 g/m 2 in men were considered to be suggestive of echocardiographic LVH. For the diastolic function measurements, pulse-wave Doppler flow was measured in the apical four chamber view, with the cursor placed near the mitral inflow and the aortic outflow, so as to get both the aortic jet and the mitral flow pattern in the same heart beat. The intraventricular relaxation time was measured from the end of the aortic outflow, to the beginning of the 'E' wave, which was the first positive wave of the mitral inflow. The 'A' wave was the second positive wave. The heights of the 'E' and 'A' waves were also calculated.
Statistical analyses
Results are expressed as mean with standard deviation (SD) or as median with interquartile range (IQR) for the normally distributed data and skewed data respectively. Data between patients and controls were analysed by the unpaired t-test or MannWhitney U-test, as appropriate. Correlations were performed by Spearman's rank correlation method. All statistical calculations were performed on a microcomputer using a commercially available statistical package (Minitab release 12, Minitab Inc., State College, PA, USA). A P-value o0.05 was considered statistically significant.
Results
A total of 31 patients (23 male, eight female; mean age 52 years) with MHT had echocardiograms that were suitable for inclusion in the study. In total, 56% of the patients were Caucasian and 32% were of Afro-Caribbean origin. The remainder were IndoAsian. The average body mass index (BMI) of the patient group was high, at 30 kg/m 2 . Of the 31 patients with MHT, 16 were not previously known to have hypertension and were not receiving treatment as their presentation with MHT was their first diagnosis of hypertension. Of those who were previously known to have hypertension, the median duration of treatment was 5 years (Table 1) . Majority of these patients had essential hypertension as the background of their MHT. One patient had renal artery stenosis, while 4 (12%) had renal failure (defined as serum creatinine greater than 160 mmol/ l). The main presenting symptom of MHT was visual disturbance (48%), while headache was the next common presenting complaint (Table 2) . None had any evidence of coronary heart disease on the basis of clinical history or ECGs. As expected, patients with MHT had a significantly higher mean systolic and diastolic blood pressure (Po0.001) as compared to the other two groups. The only other significant difference between the MHT group and the other two groups was the raised mean serum creatinine levels (Po0.001).
Echocardiography
MHT patients had significantly greater mean left atrial dimensions (P ¼ 0.002) and aortic root dimension (P ¼ 0.01), as well as LV dimensions (with the exception of the diastolic internal diameter) ( Table 3 ). MHT patients also had a higher mean LV mass and LV mass index (both Po0.001), when compared to the other two groups. The regional wall thickness was also higher in the MHT group, although not statistically significant. Patients of Afro-Caribbean origin were more likely to have an LV mass greater than 400 g (P ¼ 0.04) (Figure 1 ). Previous antihypertensive treatment did not influence the findings apart from the LA size (Table 4) .
The mean ejection fraction was significantly lower in the MHT group (Po0.001). However, this was apparent as global dysfunction, and none of the patients had regional wall motion abnormalities. The MHT patients also had a significantly lower mean E/A ratio (o1.0, suggesting possible diastolic dysfunction).
For all the hypertensives (ie MHT and nonmalignant hypertensives), the LV mass index correlated strongly with the systolic (Spearman r ¼ 0.432, Po0.001) and diastolic (r ¼ 0.486, Po0.001) BP (Figures 2 and 3 ). There were also good correlations between the Sokolow-Lyon score on ECG and the systolic (r ¼ 0.63, Po0.001) and diastolic BP (r ¼ 0.574, Po0.001) and the LV mass index on echocardiography (r ¼ 0.319, P ¼ 0.009). When analysing the MHT patient group alone, the correlations were not statistically significant in view of the small numbers (data not shown).
By the echocardiographic criteria, 93% (29 of the 31 patients) of the patients with MHT had evidence of LVH, as opposed to 38% of the treated nonmalignant hypertension and none of the normotensive controls. However, the ECG had demonstrated signs of LVH in only 19 of the 31 patients with MHT and one of the 39 patients with nonmalignant hypertension. There was evidence of LVH on the ECG in less than half of the patients who had LVH by echocardiographic criteria (Table 5 ). Only one patient had ECG evidence of LVH, which was not confirmed by echocardiography.
Discussion
The prevalence of MHT is around 1-2 cases per 100 000 population per year. 15 With the widespread use of antihypertensive agents, and the early diagnosis of hypertension, the incidence does appear to be decreasing. However, as seen in our cross-section of patients, it is possible for patients to present for the first time with MHT. Our findings are consistent with previous work of other investigators which also confirms a high prevalence of LVH among MHT patients. [16] [17] [18] Indeed, the identification of LVH in patients with MHT is of great importance, in view of the relationship between LVH and arrhythmias, as well as sudden death. 19, 20 These arrhythmias could in part explain the increased mortality seen in untreated MHT patients, 3 or in subjects where the treatment may be suboptimal. 7 The presence of severe LVH in our patients suggests that even in the undiagnosed patients, the hypertension could have been long standing but undetected. There were no significant differences in the echocardiographic parameters between those who were already on treatment and those who were untreated. It is possible that de novo MHT can occur in patients who were previously well. 6 Indeed, Shapiro et al 8, 21 reported that MHT patients who were previously undiagnosed or untreated hypertensives did not have LVH, thus leaving room for debate about the origins of MHT.
The only factor that affected the echocardiographic LV wall thickness in our cohort was ethnicity, with a higher LV mass index among patients who were of Afro-Caribbean origin. Duration of treatment, systolic or diastolic blood pressure or age did not influence any of the values. Similar findings have been reported by others. [22] [23] [24] [25] Ethnic origin must therefore be considered before labelling a person as having LVH, based on either ECG or echocardiographic criteria. Of note is the fact that there was no statistical difference in the RWT ratio (a measure of concentric LVH, as opposed to septal hypertrophy in relation to LV cavity size) among the three ethnic groups, suggesting that all had a 72 (10) 72 (15) 55 ( proportional increase in the LV wall thickness corresponding to the general cardiac size.
The prevalence of depressed LV systolic function also has implications on the management of these patients. Previous reports have suggested that the incidence of heart failure in patients with MHT was around 8%, 15 and thus, many MHT patients have asymptomatic LV dysfunction. None of our patients with MHT had either clinical or ECG evidence of myocardial ischaemia. Thus, the depressed function in MHT may be the result of the high BP, and the strain that the heart is under due to the high 26 It is known that hypertensives are more prone to develop atrial fibrillation, ventricular arrhythmias and sudden cardiac death. [27] [28] [29] [30] In these patients with MHT, the mean LA size was significantly higher than the other groups, perhaps making them more likely to develop atrial fibrillation in the future. At present, there are no available data to suggest that MHT patients develop atrial fibrillation at a rate faster than those with nonmalignant essential hypertension. Previous large follow-up studies of MHT patients do not mention the incidence of atrial fibrillation. 6, 31 Our study was limited in its cross-sectional design. Also, we do not have follow-up echocardiography in these patients to evaluate if there is any resolution of these changes with treatment or whether these changes are permanent. Further work is also needed to relate these echocardiographic findings with prognosis and outcome. Finally, this cohort of patients was chosen solely on the basis of the patients having an interpretable echocardiogram.
In conclusion, patients with MHT have significant cardiac hypertrophy, in association with systolic dysfunction, impaired relaxation and dilated left atria, irrespective of the duration of hypertension. These abnormalities may predispose MHT patients to cardiovascular complications including heart failure and cardiac arrhythmias, such as atrial fibrillation and sudden death. These findings emphasise the importance of prompt recognition and early treatment of this condition.
